Using multi-omics to improve diagnosis and treatment of urinary system tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect tumor tissue samples from patients diagnosed with urinary system carcinomas, including bladder, kidney, and prostate cancers. The study will utilize advanced techniques such as RNA-sequencing, single-cell RNA-sequencing, spatial transcriptomics, proteomics, and analysis of the intratumoral microbiome to gather comprehensive biological data. By integrating these multi-omics and multi-modal approaches, the study seeks to enhance understanding of tumor biology and improve diagnostic and treatment strategies for affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026;
2. Aged \> 18 years old;
3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignant tumor other than urinary tract tumor;
4. Unclear pathological diagnosis

Where it's running

• Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Lian Yang
• Email: yanglian@hust.edu.cn
• Phone: 18986273791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Candonilimab with Fruquintinib and Paclitaxel Albumin-Bound as second-line treatment for advanced gastric cancer

  This phase 2 trial tests whether adding candonilimab to fruquintinib and nab-paclitaxel helps people with advanced gastric or gastroesophageal junction cancer who progressed after first-line therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07920224

• Pulse Wave vs Saline Bolus EIT to measure lung perfusion in ARDS

  This study tests whether pulse wave EIT or saline bolus EIT can best show lung blood flow in ARDS patients on mechanical ventilation.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07908368

• AI-powered CT help to guide pneumonia care

  A multicenter trial tests whether using a chest CT–based AI report to guide care reduces death or need for new organ support in adults with pneumonia.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895290

• AI-assisted longitudinal CT to guide indeterminate lung nodules

  This trial tests whether giving doctors an AI report that tracks nodules over serial CT scans helps reduce unnecessary benign lung resections in patients with indeterminate nodules.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07895277

• Low-Dose CBCT AI Model for Interventions

  This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.

  Recruiting at 5 sites Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Hefei, Anhui and 4 other locations · NCT07845929

• Dalpiciclib with an aromatase inhibitor and olmesartan as first-line therapy for HR+/HER2- advanced breast cancer

  This trial tests whether adding dalpiciclib and olmesartan to an aromatase inhibitor helps people with HR+/HER2- advanced breast cancer respond to first-line treatment.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07810088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.